Abstract: Enhanced control of species of Cryptococcus, non-fermentative yeast pathogens, was achieved by chemosensitization through co-application of certain compounds with a conventional antimicrobial drug. The species of Cryptococcus tested showed higher sensitivity to mitochondrial respiratory chain (MRC) inhibition compared to species of Candida. This higher sensitivity results from the inability of Cryptococcus to generate cellular energy through fermentation. To heighten disruption of cellular MRC, octyl gallate (OG) or 2,3-dihydroxybenzaldehyde (2,3-DHBA), phenolic compounds inhibiting mitochondrial functions, were selected as chemosensitizers to pyraclostrobin (PCS; an inhibitor of complex III of MRC). The cryptococci were more susceptible to the chemosensitization (i.e., PCS + OG or 2,3-DHBA) than the Candida with all Cryptococcus strains tested being sensitive to this chemosensitization. Alternatively, only few of the Candida strains showed sensitivity. OG possessed higher chemosensitizing potency than 2,3-DHBA, where the concentration of OG required with the drug to achieve chemosensitizing synergism was much lower than that required of 2,3-DHBA. Bioassays with gene deletion mutants of the model yeast Saccharomyces cerevisiae showed that OG or 2,3-DHBA affect different cellular targets. These assays revealed mitochondrial superoxide dismutase or glutathione homeostasis plays a relatively greater role in fungal tolerance to 2,3-DHBA or OG,
acetylsalicylic acid (AcSA) or 2,3-dihydroxybenzaldehyde (2,3-DHBA) also inhibits the functions of mitochondria or mitochondrial superoxide dismutase (Mn-SOD), respectively, in fungi [15, 16] . Chemosensitization is a strategy where co-application of certain types of compounds along with a conventional antimicrobial drug increases the effectiveness of the drug [19] [20] [21] [22] . Examples include: (1) 4-methoxy-2,3,6-trimethylbenzensulfonyl-substituted D-octapeptide, which sensitizes pathogenic Candida strains to fluconazole (FLC), resulting in countering FLC resistance of clinical isolates [22] , (2) 7-chlorotetrazolo [5,1-c] benzo [1, 2, 4] triazine (CTBT), which increases the susceptibility of Candida and Saccharomyces strains to cycloheximide, 5-fluorocytosine and azole drugs [23] , (3) squalamine (a modifier of membrane integrity by increasing permeability of drugs), which enhances the susceptibility of various antibiotic-resistant and susceptible strains of Gram-negative bacteria to drugs [21] , and (4) antimycin A (AntA) and benzhydroxamic acid (BHAM), which makes Rhizopus oryzae hypersensitive to triazoles, i.e., posaconazole (PCZ) and itraconazole (ICZ), via apoptosis [24] . Collectively, these studies showed that antimicrobial drug therapy that includes chemosensitization could lead to lowering dosage levels of conventional drugs needed for control of pathogens, in both drug-resistant and susceptible strains.
Various species of Cryptococcus and Candida are human and animal pathogens. For example, cryptococcal meningitis is reported to be the leading cause of death among those infected with HIV [25] . However, one of the key differences between the yeasts in these two genera is that species of Cryptococcus are non-fermentative, while the Candida species are fermentative [16] . [26] ].) [16] PG AOX [13, 27] OG AOX [28, 29] Based on this difference, we reasoned the following: (1) When cellular MRC is disrupted by MRC-inhibitory drug(s), the Cryptococcus would show higher sensitivity than the Candida, (2) This higher sensitivity is due to the fact that the Candida can generate cellular energy also through fermentation (other than MRC), while the Cryptococcus, being non-fermentative, lack this ability, and (3) Thus, MRC could serve as an effective antifungal target especially for control of Cryptococcus pathogens.
In this study, we investigated if selected phenolic compounds/derivatives (See Table 1 ) could enhance the antifungal potency of pyraclostrobin (PCS), the most potent complex III inhibitor of MRC in our test, against Cryptococcus. Our hypothesis was that co-application of phenolic compounds/derivatives (as chemosensitizers) and PCS will negatively affect the common cellular target, i.e., functions of mitochondria, resulting in increased sensitivity of fungi. We also evaluated the potential of these chemosensitizing compounds to serve as active pharmaceutical "leads" against Cryptococcus yeasts, and compared the effectiveness of chemosensitization between Cryptococcus and Candida (See Table 2 for strains tested). Our results showed that the Cryptococcus were more susceptible to OG-or 2,3-DHBA-mediated chemosensitization to PCS than the Candida, where the chemosensitizing capacity of OG was found to be greater than that of 2,3-DHBA. 
Results and Discussion
We initially tested the effect of chemosensitization by co-applying commercial antifungal/antimalarial drugs "ATQ + proguanil" on the growth of fermenting and non-fermenting yeast pathogens. For this test, we chose representative yeast pathogens, i.e., C. albicans 90028 as a fermentor, and C. neoformans 90112 and C. gatti 4560 as non-fermentors. In protozoan parasites, co-application of proguanil (a mitochondria-modulating chemosensitizer) increased anti-parasitic activity of ATQ [31] . Noteworthy is that proguanil-mediated chemosensitization was specific for ATQ.
Proguanil did not increase the potency of other types of MRC inhibitors (e.g., myxothiazole, AntA) [31] . Thus, these results with malarial parasites (Plasmodium) indicated "drug-chemosensitizer specificity" existed during the chemosensitization process.
We used the checkerboard microdilution bioassay protocol outlined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [32] , with various concentrations of ATQ (0.25, 0.5, 1, 2, 4, 8, 16 μg/mL) and proguanil (0.25, 0.5, 1, 2, 4, 8, 16 μg/mL). Our results showed that: (1) Independent application of ATQ or proguanil, alone, did not exhibit discernable growth inhibition in any of the test yeast strains, even at the highest concentration (i.e., 16 μg/mL), and also (2) Co-application of ATQ with proguanil did not enhance the antifungal activity of either compounds, indicating no chemosensitization occurred by "ATQ + proguanil" co-treatment in these strains (Data not shown).
In the model yeast Saccharomyces cerevisiae, nine cellular transporters required for sequestering toxic drugs/compounds out of the cell need to be knocked out to exhibit ATQ sensitivity [33] . This indicates active drug-detoxification systems do operate in S. cerevisiae. We surmised that pathogenic yeasts, i.e., Cryptococcus or Candida, might also operate similar type(s) of detoxification system(s), enabling these pathogens to escape from ATQ/proguanil-triggered toxicity. Therefore, we performed chemosensitization tests using other types of MRC inhibitors with co-application of phenolic compounds (i.e., OG, PG, 2,3-DHBA, AcSA; See Table 1 ) as chemosensitizers.
PCS Is the Most Potent MRC Inhibitor in Cryptococcus
First, we identified the potency of MRC inhibitors tested against yeast pathogens. Antifungal efficacy was compared among 12 different MRC inhibitors disrupting one of the five different components of MRC, i.e., complexes I to IV or AOX (See Table 3 , Figure 1 ). The level of differential sensitivity between fermenting (Candida) and non-fermenting (Cryptococcus) yeasts to the MRC inhibitors was determined by an agar plate-based yeast dilution bioassay (See Experimental section). We initially examined (1) three fermentors: C. albicans 90028, C. glabrata 90030, C. krusei 6258 and (2) two non-fermentors: C. neoformans 90112, C. gatti MYA-4560.
MRC inhibitors targeting complex I, III or IV reduced the growth of the Cryptococcus, with differing levels of fungal sensitivity (Table 3, Figure 2a ). For example, when C. neoformans 90112 was treated with complex III inhibitors, growth was inhibited by 100 to 1000 times more compared to controls (i.e., log 10 dilution score of "no treatment" controls was "6" [i.e., yeast cells appeared at the highest dilution level of 10 6 ] vs. log 10 score of "treatments" was "3-4" [i.e., cells did not appear at dilution levels greater than10 3 -10 4 ]), depending on types of complex III inhibitors applied. Also, rotenone (a complex I inhibitor) and Na-azide (a complex IV inhibitor) inhibited the growth of C. neoformans 90112 at cell dilution levels above 10 3 times. Growth of C. gatti 4560 was also decreased by four different MRC inhibitors (Table 3) . However, unlike the results of C. neoformans 90112, AntA and AZS did not inhibit the growth of C. gatti 4560 (Table 3) . Moreover, besides carboxin, which inhibited C. neoformans 90112, both complex II and AOX inhibitors did not discernably inhibit the growth of C. neoformans 90112 or C. gatti 4560 (See also Figure 2a ).
Based on these initial bioassays, rotenone, Kre-Me, PCS and Na-azide (exhibiting antifungal activity against both C. neoformans 90112 and C. gatti 4560) were selected for further evaluation for antifungal potency against additional test strains (i.e., seven additional Cryptococcus and six additional Candida strains) (See Figure 2b) . A similar trend of growth inhibition was found in these additional Cryptococcus strains with PCS and rotenone, while Kre-Me and Na-azide showed almost no effect. The growth of the additional Candida strains was not noticeably affected by any of these same treatments. In summary: (1) PCS possessed the highest antifungal activity (Average log 10 dilution score = 3.4 ± 0.9, this lowest average log 10 score was based upon the results using nine Cryptococcus strains shown in Figure 2a ,b), followed by rotenone (average log 10 score = 4.6 ± 1.2); (2) as expected, the growth of the Candida (fermenting yeasts) was not affected by any of the MRC inhibitors tested (Table 3 ; Figure 2a ,b), and (3) thus, we chose PCS as the most potent MRC-inhibitory drug against Cryptococcus in our chemosensitization study. TTFA, Thenoyltrifluoroacetone; 3-NPA, 3-Nitropropionic acid; BHAM, Benzhydroxamic acid; SHAM, Salicylhydroxamic acid; AntA, Antimycin A; Kre-Me, Kresoxim methyl; PCS, Pyraclostrobin; AZS, Azoxystrobin; KCN, Potassium cyanide; Na-azide, Sodium azide. Numbers represented highest dilution level (log 10 ) where cell growth was visible. Numbers in bold show cell growth was inhibited (viz., < 6). Table 3 ). (b) Yeast dilution bioassay showing PCS is the most potent MRC inhibitor tested, followed by rotenone (Cell dilution level showing visible growth equates to antifungal potency [higher dilution score with visible growth = lower potency]; PCS, average log 10 score = 3.4 ± 0.9 vs. rotenone, average log 10 score = 4.6 ± 1.2. Average log 10 score was determined in nine Cryptococcus strains). As observed in panel (a), Candida strains did not exhibit growth inhibition to any of the MRC inhibitors tested.
Antifungal Chemosensitization Tests in Yeast Pathogens

Selection of OG and 2,3-DHBA as the Most Potent Chemosensitizers
Next, we identified the most potent antifungal chemosensitizer(s), among four phenolic compounds listed in Table 1 , which inhibit functions of fungal mitochondria. Based on agar plate-based yeast dilution bioassay (See Experimental section), we determined minimum inhibitory concentrations (MICs) of OG, PG, 2,3-DHBA and AcSA. As shown in Table 4 , OG and 2,3-DHBA possessed the highest antifungal activity (i.e., low MIC values) compared to PG or AcSA. Of note, Candida strains were generally more tolerant to the phenolic compounds tested compared to Cryptococcus strains. Based on these results, OG and 2,3-DHBA were selected as the chemosensitizers to test with PCS. 
Chemosensitization in Cryptococcus: 2,3-DHBA + PCS
Antifungal chemosensitization was tested based on the EUCAST checkerboard microdilution bioassay protocol [32] (concentrations of compound examined were listed in Experimental section). For MICs, "synergistic" Fractional Inhibitory Concentration Indices (FICIs; see Experimental section for calculations) (i.e., FICI ≤ 0.5) were found between 2,3-DHBA and PCS for most Cryptococcus strains (Table 5 ). Despite the absence of calculated synergism, as determined by "indifferent" interactions [34] (Table 5) , there was increased antifungal activity of 2,3-DHBA and PCS (i.e., chemosensitization; FICI = 0.8) in C. neoformans 4567, which was reflected in lowered MICs of 2,3-DHBA or PCS when combined. However, for Minimum Fungicidal Concentrations (MFCs), "synergistic" Fractional Fungicidal Concentration Indices (FFCIs) (at the level of ≥ 99.9% fungal death) between 2,3-DHBA and PCS occurred only in C. neoformans strains 4565 and CN24 (Table 5) . Therefore, results indicated that the 2,3-DHBA-mediated chemosensitization with PCS is fungistatic, not fungicidal (i.e., Mean MFC combined for 2,3-DHBA or PCS/ Mean MIC combined for 2,3-DHBA or PCS was > 4 [See [35] for reference]), in most Cryptococcus strains tested. The effect of "2,3-DHBA + PCS" chemosensitization was also examined in the Candida where "no synergistic" FICIs were found. However, there was increased antifungal activity with 2,3-DHBA + PCS (i.e., chemosensitization) in five strains (i.e., all three C. krusei strains, C. albicans CAN242 and C. glabrata CAN252), as reflected in lower MICs of each compound when co-applied (Table 6 ) than when applied alone. However, FICIs for the remaining four Candida strains and FFCIs for all Candida were 2.0 (i.e., no compound interactions occurred at all), indicating these fermenting yeast strains were relatively tolerant to any chemosensitization exerted by "2,3-DHBA + PCS." Table 6 . Antifungal chemosensitization of 2,3-DHBA (mM) to PCS (μg/mL) tested against Candida: EUCAST-based microdilution bioassays. 
Chemosensitization in Cryptococcus: OG + PCS
Next, chemosensitization efficacy of "OG + PCS" in Cryptococcus was evaluated. For MICs, synergistic FICIs were achieved for most of the Cryptococcus strains (Table 7) . Similar to the results for "2,3-DHBA + PCS", the only exception for achieving synergism was C. neoformans 4567, which was determined to be an "indifferent" interaction. However, increased antifungal activity of OG and PCS (i.e., chemosensitization; FICI = 0.6) could be achieved in C. neoformans 4567, resulting in lowered MICs of OG or PCS when co-applied.
For MFCs, synergistic FFCIs (at the level of ≥ 99.9% fungal death) between OG and PCS occurred in all Cryptococcus strains (Table 7) , reflecting the most potent antifungal activity of OG, as determined in Table 4 . Most notable is that the concentration of OG needed to achieve synergism with PCS was much lower than that for 2,3-DHBA, i.e., chemosensitizing potency (higher to lower, as indicated by lower concentrations required) = OG (0.01-0.02 mM) > 2,3-DHBA (0.2-1.6 mM; See also Table 5 ). Table 7 . Antifungal chemosensitization of OG (mM) to PCS (μg/mL) tested against Cryptococcus strains: EUCAST-based microdilution bioassays. 
Chemosensitization in Candida: OG + PCS
The chemosensitization effect of "OG + PCS" was further examined in the Candida strains. For MICs, "synergistic" FICIs were found in four strains, i.e., all three C. krusei strains and C. glabrata CAN252 (Table 8 ). This synergism was not detected with "2,3-DHBA + PCS", further reflecting the higher antifungal activity of OG than 2,3-DHBA (See also Table 6 ). Despite the "indifferent" interaction, increased antifungal activity of OG and PCS (i.e., chemosensitization; FICI = 0.6) occurred in C. albicans CAN242, as determined in lowered MICs of OG or PCS when combined (Table 8) .
Of note, the trends of compound interactions of OG + PCS for MICs in Table 8 were congruent with "2,3-DHBA + PCS" chemosensitization (Table 6 ). For both "2,3-DHBA + PCS" and "OG + PCS", incremental increase of growth inhibition occurred in five common strains, i.e., all three C. krusei strains, C. albicans CAN242 and C. glabrata CAN252 (Tables 6 and 8 ). This indicated that strain specificity to chemosensitization also exists. This is reflected in the level of differential vulnerability of each strain to chemosensitization (See also FICIs of C. neoformans 4567 in Tables 5 and 7 , showing lower sensitivity of this strain to both OG-and 2,3-DHBA-mediated chemosensitization compared to other Cryptococcus strains).
For MFCs, synergistic FFCIs (at the level of ≥99.9% fungal death) between OG and PCS were achieved in C. krusei CAN82 and C. glabrata CAN252. While the FFCI of C. krusei 6258 was scored as "indifferent", there was increased antifungal activity of OG and PCS (i.e., chemosensitization; FFCI = 0.6) with this strain. FFCIs for the remaining strains were "indifferent", and as observed in "2,3-DHBA + PCS" assays, Candida strains were more tolerant to "OG + PCS" chemosensitization compared to Cryptococcus strains. The results of all chemosensitization tests (i.e., PCS + 2,3-DHBA or OG in both Cryptococcus and Candida strains) are summarized in Table 9 . Exemplary MFC test results, based on chemosensitization (PCS + OG or 2,3-DHBA) performed in Cryptococcus or Candida strains, are provided in Figure 3 . Table 9 . SUMMARY: Antifungal chemosensitization of OG or 2,3-DHBA (mM) to PCS (μg/mL) tested against Cryptococcus or Candida strains determined by EUCAST-based microdilution bioassays. Data shown are mean values derived from Table 5 [37, 38] ), (2) sod2Δ (mitochondrial superoxide dismutase, Mn-SOD), (3) trr1Δ (cytoplasmic thioredoxin reductase), (4) trr2Δ (mitochondrial thioredoxin reductase), and (5) tsa1Δ (thioredoxin peroxidase) (See Saccharomyces Genome Database [30] ).
Of the five deletion mutants, yap1Δ was hypersensitive to OG (log 10 = 4), while sod2Δ was hypersensitive to 2,3-DHBA (log 10 = 5) (Figure 4 ) (see also [15] ). These results indicate OG or 2,3-DHBA affect different cellular components in fungi, where Mn-SOD plays a relatively greater role in fungal tolerance to 2,3-DHBA, while glutathione homeostasis, etc., protects cells from OG-induced toxicity, compared to the other genes represented. Further studies, such as microarray-based chemogenomic analysis, inclusion of more gene deletion mutants, etc., are warranted to determine the precise mechanism of action of OG or 2,3-DHBA during chemosensitization. : yeast dilution rates). Results showed the sensitive responses of yap1Δ to OG and sod2Δ to 2,3-DHBA, respectively.
Experimental
Yeast Strains
Yeast strains (Cryptococcus-C. neoformans, C. gatti; Candida-C. albicans, C. glabrata, C. krusei; Saccharomyces cerevisiae; See CFU/mL) were performed using broth microdilution protocols according to methods outlined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [32] . Minimum inhibitory concentration (MIC) for chemosensitization was defined as the lowest concentration of agent(s) where no fungal growth was visible at 24 and 48 h. All bioassays were performed in triplicate. Statistical analysis was based on [36] . Microtiter plate (microdilution) bioassay was also performed to determine chemosensitizing activity of proguanil (0. 25 These assays were performed in duplicate on SG agar following previously described protocols [15] was equivalent to a 10-fold difference in the sensitivity of the yeast strain to the treatment.
Statistical Analysis
Statistical analyses, e.g., chemosensitization vs. no chemosensitization, were performed based on [36] .
Conclusions
In summary, OG-or 2,3-DHBA-based chemosensitization can enhance antifungal activity of PCS in Cryptococcus and Candida. Our results showed that: (1) All Cryptococcus strains (non-fermentors) were sensitive to PCS + OG or 2,3-DHBA; (2) Only selected Candida strains (three C. krusei strains, C. albicans CAN242, C. glabrata CAN252) (fermentors) were sensitive to PCS + OG or 2,3-DHBA; (3) OG was a more potent chemosensitizer than 2,3-DHBA to PCS, where the concentration of OG required to achieve "synergism" was much lower (≥20 times lower) than 2,3-DHBA in either Cryptococcus or Candida strains; (4) "chemosensitization -strain specificity" exists, which reflects differential vulnerability of tested strains to the chemosensitization; (5) OG or 2,3-DHBA disrupt different cellular components in fungi, where Mn-SOD plays a role in fungal tolerance to 2,3-DHBA, while glutathione homeostasis, etc., are responsible for protecting cells from OG-triggered toxicity.
The MRC is recently recognized as a new target for development of clinical antimycotics [24, 39] . For example, co-application of AntA (MRC-inhibitory) and BHAM (AOX-inhibitory) significantly increased the activity of triazole drugs, potentiating the antifungal activity of the drugs as fungicidal in R. oryzae (causative agent of mucormycosis) [24] . Also, inhibition of MRC of C. parapsilosis (causing neonatal and device-related infections; See [39] and references therein) enhances susceptibility of this fungal pathogen to caspofungin, a cell wall-targeting drug [39] . Thus, use of a chemosensitizer, as described in this study, would lower the effective dose of an MRC-inhibitory drug, thus lowering potential side effects of these drugs and others that might be co-applied (i.e., azoles, caspofungin, etc.). This lower dosage would render treatment less expensive and safer, thus making their use more acceptable.
In conclusion, OG and/or 2,3-DHBA show potential to serve as antifungal chemosensitizers that in combination with PCS greatly enhance antifungal activity. This capacity was shown to be most effective against Cryptococcus, etiologic agents for the leading cause of death among those suffering from immunocompromised disorders. Chemosensitizers, especially those proven to be safe compounds, such as natural phenolic agents or their structural derivatives, could serve as potential "leads" against yeast pathogens for more effective treatment of mycoses using MRC inhibitory drugs. Determination of precise mechanisms of action of chemosensitization as well as identification of effective MRC-inhibitory drugs which selectively interfere with fungal mitochondrial function, and not human (mammalian), must be ensured through future study.
